Skip to content 
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. more
| Time Frame | ATYR | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -0.9% | -1.08% | -1.38% |
| 1-Month Return | 26.19% | -0.47% | -1.81% |
| 3-Month Return | 24.95% | 2.13% | 1.38% |
| 6-Month Return | -82.7% | 17.04% | 5.68% |
| 1-Year Return | -75.18% | 6.56% | 11.74% |
| 3-Year Return | -59.5% | 16.78% | 65.15% |
| 5-Year Return | -85.54% | 34.34% | 73.68% |
| 10-Year Return | -98.53% | 137.88% | 260.03% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 10.46M | - | 10.39M | 353.00K | 235.00K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":99.34,"profit":true},{"date":"2023-12-31","value":3.38,"profit":true},{"date":"2024-12-31","value":2.25,"profit":true}] |
| Cost of Revenue | 17.29M | 1.30M | 1.70M | 2.74M | 1.54M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.54,"profit":true},{"date":"2022-12-31","value":9.8,"profit":true},{"date":"2023-12-31","value":15.85,"profit":true},{"date":"2024-12-31","value":8.91,"profit":true}] |
| Gross Profit | (6.84M) | (1.30M) | 8.69M | 353.00K | 235.00K | [{"date":"2020-12-31","value":-78.66,"profit":false},{"date":"2021-12-31","value":-15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.06,"profit":true},{"date":"2024-12-31","value":2.7,"profit":true}] |
| Gross Margin | (65.38%) | - | 83.68% | 100.00% | 100.00% | [{"date":"2020-12-31","value":-65.38,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":83.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 9.07M | 32.71M | 55.09M | 55.27M | 68.15M | [{"date":"2020-12-31","value":13.32,"profit":true},{"date":"2021-12-31","value":48,"profit":true},{"date":"2022-12-31","value":80.84,"profit":true},{"date":"2023-12-31","value":81.1,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | (15.91M) | (34.02M) | (46.40M) | (54.92M) | (67.91M) | [{"date":"2020-12-31","value":-1591100000,"profit":false},{"date":"2021-12-31","value":-3401500000,"profit":false},{"date":"2022-12-31","value":-4640400000,"profit":false},{"date":"2023-12-31","value":-5491900000,"profit":false},{"date":"2024-12-31","value":-6791400000,"profit":false}] |
| Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Pre-Tax Income | (16.23M) | (33.78M) | (45.34M) | (50.40M) | (64.02M) | [{"date":"2020-12-31","value":-1623000000,"profit":false},{"date":"2021-12-31","value":-3377700000,"profit":false},{"date":"2022-12-31","value":-4534300000,"profit":false},{"date":"2023-12-31","value":-5039700000,"profit":false},{"date":"2024-12-31","value":-6402200000,"profit":false}] |
| Income Taxes | (6.00K) | (9.00K) | (5.00K) | (8.00K) | - | [{"date":"2020-12-31","value":-600000,"profit":false},{"date":"2021-12-31","value":-900000,"profit":false},{"date":"2022-12-31","value":-500000,"profit":false},{"date":"2023-12-31","value":-800000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (16.23M) | (33.78M) | (45.34M) | (50.40M) | (64.02M) | [{"date":"2020-12-31","value":-1623000000,"profit":false},{"date":"2021-12-31","value":-3377700000,"profit":false},{"date":"2022-12-31","value":-4534300000,"profit":false},{"date":"2023-12-31","value":-5039700000,"profit":false},{"date":"2024-12-31","value":-6402200000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (16.22M) | (33.77M) | (45.34M) | (50.39M) | (64.02M) | [{"date":"2020-12-31","value":-1622400000,"profit":false},{"date":"2021-12-31","value":-3376800000,"profit":false},{"date":"2022-12-31","value":-4533800000,"profit":false},{"date":"2023-12-31","value":-5038900000,"profit":false},{"date":"2024-12-31","value":-6402300000,"profit":false}] |
| EPS (Diluted) | (1.59) | (1.88) | (1.60) | (0.96) | (0.86) | [{"date":"2020-12-31","value":-159,"profit":false},{"date":"2021-12-31","value":-188,"profit":false},{"date":"2022-12-31","value":-160,"profit":false},{"date":"2023-12-31","value":-96,"profit":false},{"date":"2024-12-31","value":-86.42,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| ATYR | |
|---|---|
| Cash Ratio | 5.75 |
| Current Ratio | 5.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ATYR | |
|---|---|
| ROA (LTM) | -49.59% |
| ROE (LTM) | -103.49% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| ATYR | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ATYR | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 459.45 |
| P/B | 1.09 |
| Price/FCF | NM |
| EV/R | 49.75 |
| EV/Ebitda | NM |
aTyr Pharma, Inc. (ATYR) share price today is $0.8939
Yes, Indians can buy shares of aTyr Pharma, Inc. (ATYR) on Vested. To buy
Yes, you can purchase fractional shares of aTyr Pharma, Inc. (ATYR) via the Vested app. You can start investing in aTyr Pharma, Inc. (ATYR) with a minimum investment of $1.
You can invest in shares of aTyr Pharma, Inc. (ATYR) via Vested in three simple steps:
The 52-week high price of aTyr Pharma, Inc. (ATYR) is $7.29. The 52-week low price of aTyr Pharma, Inc. (ATYR) is $0.64.
The price-to-earnings (P/E) ratio of aTyr Pharma, Inc. (ATYR) is
The price-to-book (P/B) ratio of aTyr Pharma, Inc. (ATYR) is 1.09
The dividend yield of aTyr Pharma, Inc. (ATYR) is 0.00%
The market capitalization of aTyr Pharma, Inc. (ATYR) is $87.30M
The stock symbol (or ticker) of aTyr Pharma, Inc. is ATYR
Consider the share price of aTyr Pharma, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether aTyr Pharma, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in aTyr Pharma, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the aTyr Pharma, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of aTyr Pharma, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that aTyr Pharma, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
